Effect of Excede® Administered to Calves at Arrival in the Feedlot on Performance and Respiratory Disease

Authors

Joshua R. Benton, University of Nebraska-LincolnFollow
Galen E. Erickson, University of Nebraska-LincolnFollow
Terry J. Klopfenstein, University of Nebraska-LincolnFollow
Matt K. Luebbe, University of Nebraska - LincolnFollow
David R. Smith, University of Nebraska-LincolnFollow
Gary E. Sides, Pfizer Animal Health, New York, N.Y.
Lonty Bryant, Pfizer Animal Health, New York, N.Y.

Date of this Version

January 2008

Comments

Published in 2008 Nebraska Beef Cattle Report. Copyright © 2007 The Board of Regents of the University of Nebraska.

Abstract

In a clinical trial where cattle were either given Excede® or not on arrival, ADG increased and F:G was numerically improved for cattle that received Excede compared to control cattle. There were no differences between initial or final BW, or DMI observed during the receiving period due to the administration of Excede. The incidence of bovine respiratory disease (BRD) for the 32 days of the study was 4.4% for cattle that received Excede at arrival and was different compared to the control cattle which was 12.2%. The correlation (-0.157) between DMI and morbidity observed in this study was not significant. Metaphylactic treatment with Excede improved ADG and effectively reduced the cumulative incidence of BRD during the study.